Terence Ching

Terence Ching, PhD, is an Instructor in the Department of Psychiatry at Yale School of Medicine. He co-leads psilocybin clinical trials for OCD and other disorders through the ENACT Lab and Yale Program for Psychedelic Science. His expertise spans fear/trauma-based disorders, culturally attuned care, and psychedelic therapies.

Education: PhD in Clinical Psychology from the University of Connecticut (2021), Master’s and Bachelor’s in Psychology from National University of Singapore.

Research Interests: Focuses on OCD, anxiety/PTSD, exposure-based CBT, and psychedelic-assisted therapies. Specializes in culturally attuned approaches for marginalized communities, including LGBTQ+ and Asian American populations. Active in translational studies linking neuroscience to therapeutic outcomes.

Recent Articles: Published 43+ peer-reviewed papers on topics including MDMA/MDMA efficacy in PTSD, psilocybin protocols for OCD, and racial/ethnic disparities in mental healthcare. Current work emphasizes mechanism studies and equity in psychedelic medicine access.

Grants & Labs: Involved in NIH-funded studies on psychedelic safety. Serves as Principal Investigator for multiple clinical trials (e.g., psilocybin dosing in OCD, ketamine-assisted psychotherapy).

Labs/Teams: ENACT Lab (Emerging Novel Applications for Consciousness-Altering Therapeutics), Yale OCD Research Clinic.